Your browser is no longer supported. Please, upgrade your browser.
Settings
RGEN Repligen Corporation daily Stock Chart
RGEN [NASD]
Repligen Corporation
Index- P/E144.76 EPS (ttm)0.57 Insider Own0.90% Shs Outstand51.06M Perf Week2.57%
Market Cap4.18B Forward P/E75.73 EPS next Y1.08 Insider Trans-5.13% Shs Float46.97M Perf Month-12.41%
Income26.60M PEG5.79 EPS next Q0.19 Inst Own89.30% Short Float8.98% Perf Quarter-1.51%
Sales232.80M P/S17.94 EPS this Y-23.80% Inst Trans13.05% Short Ratio6.61 Perf Half Y38.84%
Book/sh18.96 P/B4.31 EPS next Y11.34% ROA3.10% Target Price107.00 Perf Year41.80%
Cash/sh4.09 P/C19.99 EPS next 5Y25.00% ROE3.90% 52W Range48.26 - 99.25 Perf YTD55.08%
Dividend- P/FCF102.61 EPS past 5Y-5.90% ROI2.90% 52W High-17.59% Beta1.10
Dividend %- Quick Ratio1.90 Sales past 5Y23.30% Gross Margin55.60% 52W Low69.48% ATR3.26
Employees548 Current Ratio2.20 Sales Q/Q48.20% Oper. Margin16.30% RSI (14)39.93 Volatility3.11% 3.97%
OptionableYes Debt/Eq0.12 EPS Q/Q171.30% Profit Margin11.40% Rel Volume12.60 Prev Close82.41
ShortableYes LT Debt/Eq0.00 EarningsAug 01 BMO Payout0.00% Avg Volume638.13K Price81.79
Recom1.70 SMA20-6.04% SMA50-8.09% SMA20017.55% Volume8,043,357 Change-0.75%
Aug-28-19Reiterated First Analysis Sec Outperform $95 → $107
Aug-23-19Resumed Stephens Overweight
Jul-22-19Upgrade H.C. Wainwright Neutral → Buy $110
Dec-17-18Upgrade CL King Neutral → Buy
Nov-12-18Downgrade CL King Buy → Neutral
Sep-26-18Initiated H.C. Wainwright Neutral $49
Dec-08-17Initiated Citigroup Buy $45
Dec-05-17Initiated JP Morgan Overweight $42
Nov-13-17Initiated CL King Buy
Oct-02-17Upgrade First Analysis Sec Equal-Weight → Overweight $47
Jul-21-17Initiated William Blair Outperform
Feb-13-17Upgrade Piper Jaffray Neutral → Overweight
Feb-22-16Initiated Craig Hallum Buy
Nov-06-15Downgrade Jefferies Buy → Hold
Apr-23-15Reiterated Jefferies Buy $25 → $38
Mar-07-11Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Jun-30-09Initiated Merriman Buy
Jun-12-08Reiterated Rodman & Renshaw Mkt Outperform $11 → $9
Sep-10-07Reiterated Rodman & Renshaw Mkt Outperform $6 → $8
Apr-12-07Reiterated Rodman & Renshaw Mkt Outperform $5 → $6
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-11-19 07:15PM  Repligen Corp (RGEN) CEO Anthony Hunt Sold $996,546 of Shares GuruFocus.com
Sep-09-19 02:19PM  Here's Why Repligen Has Dropped as Much as 13.1% Today Motley Fool -11.66%
Sep-06-19 06:00PM  S&P Dow Jones Indices Announces Nine Companies Set to Join S&P MidCap 400; Ten Companies to Join S&P SmallCap 600 PR Newswire
Aug-30-19 06:47AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Aug-28-19 07:11AM  3 Stocks to Buy and Hold for Decades Motley Fool
Aug-27-19 03:16PM  With EPS Growth And More, Repligen (NASDAQ:RGEN) Is Interesting Simply Wall St.
12:18AM  Edited Transcript of RGEN earnings conference call or presentation 1-Aug-19 12:30pm GMT Thomson Reuters StreetEvents
Aug-16-19 07:11AM  3 Growth Stocks for In-the-Know Investors Motley Fool
Aug-08-19 10:13AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
Aug-05-19 10:39AM  Repligen Grows Revenue 48% in Q2 Motley Fool
06:37AM  With A 3.0% Return On Equity, Is Repligen Corporation (NASDAQ:RGEN) A Quality Stock? Simply Wall St.
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -5.13%
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
02:24AM  Repligen (RGEN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
09:25AM  Repligen (RGEN) Q2 Earnings and Revenues Surpass Estimates Zacks
07:30AM  Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
07:02AM  Powell Gives Space for Growth, Market Overreacts: 5 Picks Zacks
Jul-30-19 10:58AM  The Zacks Analyst Blog Highlights: Repligen, Tandem Diabetes Care, Telephone and Data Systems, Sunoco and Rent-A-Center Zacks
Jul-29-19 07:58AM  5 Top Picks on Three Key Takeaways From Q2 U.S. GDP Zacks
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
10:33AM  Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
Jul-23-19 04:01PM  Repligen to Report Second Quarter 2019 Financial Results GlobeNewswire
10:56AM  Is a Beat in Store for Repligen (RGEN) This Earnings Season? Zacks
Jul-19-19 07:42PM  Repligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters Options GlobeNewswire
09:30AM  Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-18-19 11:18AM  NuCana Initiates Dosing in Phase I Study for Solid Tumors Zacks
Jul-17-19 08:10AM  Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? Zacks
12:14AM  Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024 GlobeNewswire
Jul-15-19 04:02PM  Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes GlobeNewswire
Jul-13-19 07:28AM  These 6 stocks in the S&P 1500 have more than doubled in 12 months MarketWatch
Jul-12-19 09:25AM  Repligen Corporation (NASDAQ:RGEN): Financial Strength Analysis Simply Wall St.
Jul-11-19 02:05PM  Edited Transcript of RGEN earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
12:10PM  Here's Why Repligen Gained 62.9% in the First Half of 2019 Motley Fool
Jul-09-19 09:54AM  Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 Zacks
08:45AM  Here is Why Growth Investors Should Buy Repligen (RGEN) Now Zacks
Jul-05-19 09:21AM  The Zacks Analyst Blog Highlights: Core-Mark, Repligen, Aaron's, HubSpot and Quanex Building Products Zacks
Jul-03-19 09:12AM  U.S. Economy Likely to Sustain Longest Expansion: 5 Top Picks Zacks
Jul-02-19 05:09PM  Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx Zacks
Jun-27-19 10:18AM  Inovio Up on Enrollment Closure in Cervical Dysplasia Study Zacks
Jun-26-19 06:17PM  Pacira Gets EMA Acceptance for Pain Management Drug Exparel Zacks
06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
Jun-21-19 09:52AM  Repligen Corporation (RGEN) Shares March Higher, Can It Continue? Zacks
Jun-20-19 09:35AM  Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks
Jun-19-19 09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks
08:31AM  Wall Street Foresees a Fed Rate Cut: Winners & Losers Zacks
Jun-14-19 02:59PM  7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
Jun-13-19 10:26AM  NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag Zacks
Jun-12-19 01:24PM  How Many Repligen Corporation (NASDAQ:RGEN) Shares Have Insiders Sold, In The Last Year? Simply Wall St.
10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
08:45AM  Looking for a Growth Stock? 3 Reasons Why Repligen (RGEN) is a Solid Choice Zacks
08:00AM  Investment Opportunities Easier To Find After Market Pullback, Says Neuberger Berman's Ken Turek Investor's Business Daily
Jun-06-19 10:33AM  BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady Zacks
10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
Jun-05-19 09:44AM  The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne Zacks
Jun-04-19 05:30PM  Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR Zacks +5.63%
02:12PM  5 Biotech Stocks to Buy Right Now Zacks
10:03AM  Repligen to Present at Jefferies 2019 Healthcare Conference GlobeNewswire
09:58AM  The Zacks Analyst Blog Highlights: HEICO, Group 1 Automotive, Rent-A-Center, Repligen and Strategic Education Zacks
Jun-03-19 08:12AM  U.S. Heading for Largest Economic Expansion: 5 Top Picks Zacks
May-30-19 04:51PM  Mesoblast Starts Rolling BLA Submission for Remestemcel-L Zacks
04:11PM  How IBD Called The Stock Market Correction Quickly And Where It May Go From Here Investor's Business Daily
May-24-19 05:11PM  IBD Stock Of The Day Nearly Triples Its Rivals' Performance This Year Investor's Business Daily
04:51PM  Why Is No One Talking About Repligen Stock? Motley Fool
10:15AM  Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems Zacks
May-23-19 08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Repligen (RGEN) Zacks
May-15-19 11:07AM  Mallinckrodt Ends Enrollment in Phase III for Terlipressin Zacks
May-10-19 10:23AM  Repligen (RGEN) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 08:55AM  Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates Zacks
07:43AM  Repligen: 1Q Earnings Snapshot Associated Press
07:30AM  Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance GlobeNewswire
06:30AM  Repligen Corp. to Host Earnings Call ACCESSWIRE
May-08-19 03:03PM  Is Repligen's (NASDAQ:RGEN) Share Price Gain Of 273% Well Earned? Simply Wall St.
11:39AM  Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store? Zacks
May-06-19 03:52PM  Turtle Beach (HEAR) to Report Q1 Earnings: What's in Store? Zacks
May-02-19 02:20PM  Repligen to Report First Quarter 2019 Financial Results GlobeNewswire
Apr-30-19 07:36PM  Repligen Corporation Prices Public Offering of Shares of Common Stock GlobeNewswire
Apr-29-19 04:19PM  Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
12:09PM  Heres What Hedge Funds Think About Repligen Corporation (RGEN) Insider Monkey
Apr-26-19 04:28PM  Why Sony, Repligen, and Capital One Financial Jumped Today Motley Fool +20.35%
07:30AM  Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results GlobeNewswire
Apr-22-19 06:18AM  Repligen CEO got 356 percent pay bump for 2018 American City Business Journals
Apr-10-19 11:36AM  Before You Buy Repligen Corporation (NASDAQ:RGEN), Consider Its Volatility Simply Wall St.
Mar-29-19 01:00PM  3 Stocks to Buy and Hold for Decades Motley Fool
Mar-25-19 10:35AM  Is This Under-the-Radar Biotech Stock a Buy Near an All-Time High? Motley Fool
Mar-12-19 11:53AM  What Should Investors Know About Repligen Corporations (NASDAQ:RGEN) Future? Simply Wall St.
Mar-01-19 04:48PM  Repligen Corp (RGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com +5.51%
Feb-26-19 02:15AM  Edited Transcript of RGEN earnings conference call or presentation 21-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Feb-21-19 02:48PM  Repligen Corp (RGEN) Q4 2018 Earnings Conference Call Transcript Motley Fool
10:45AM  Repligen (RGEN) Matches Q4 Earnings Estimates Zacks
08:02AM  Repligen: 4Q Earnings Snapshot Associated Press
07:30AM  Repligen Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Feb-15-19 07:30AM  Repligen to Report Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Jan-30-19 11:48AM  Is Repligen Corporations (NASDAQ:RGEN) Liquidity Good Enough? Simply Wall St.
Jan-28-19 08:00AM  Today's Research Reports on Trending Tickers: Incyte and Repligen ACCESSWIRE -5.14%
Jan-25-19 12:21PM  3 Pick-and-Shovel Biotechnology Stocks Motley Fool
Jan-24-19 06:40PM  How to Play It Safe in Biotech Motley Fool
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. The company also provides chromatography products comprising OPUS pre-packed chromatography columns, which are used in the purification of antibodies, recombinant proteins, and vaccines; and OPUS PD smaller-scale columns that are used in the high throughput process development screening, viral validation studies, and scale down validation of chromatography processes. Its chromatography products also comprise ELISA kits, which are analytical test kits to detect the presence of proteins and growth factors; chromatography resins under the CaptivA brand; and liquid chromatography products under the Spectra/Chrom brand. In addition, the company offers filtration products, such as XCell alternating tangential flow systems that are filtration devices used in upstream processes to remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest; Sius tangential flow filters line of cassettes used in downstream biologic drug purification and formulation processes; KrosFlo line of hollow-fiber cartridges and TFF systems; Spectra/Por portfolio of laboratory and process dialysis products; and Pro-Connex single-use hollow-fiber module-bag-tubing sets. Repligen Corporation sells its bioprocessing products to life sciences companies, biopharmaceutical companies, and contract manufacturing organizations. It has a collaboration agreement with Navigo Proteins GmbH and Sartorius Stedim Biotech to develop multiple affinity ligands. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hunt AnthonyChief Executive OfficerSep 09Sale82.4012,094996,521203,013Sep 11 04:58 PM
DAWES KAREN ADirectorJun 17Option Exercise4.9620,00099,200118,329Jun 19 07:00 PM
DAWES KAREN ADirectorJun 17Sale77.351,295100,168117,034Jun 19 07:00 PM
COOPER GLENN L MDDirectorMay 23Sale66.945,000334,71535,709May 28 04:17 PM
Snodgres JonChief Financial OfficerMar 25Sale58.546,467378,60220,534Mar 27 04:50 PM
Hunt AnthonyChief Executive OfficerMar 18Sale59.6314,550867,633215,107Mar 20 08:20 AM
Snodgres JonChief Financial OfficerMar 05Sale58.522,645154,78527,001Mar 05 05:34 PM
Hunt AnthonyChief Executive OfficerMar 05Sale58.5013,000760,500229,657Mar 05 05:35 PM
KURIYEL RALFSenior VP, R&DMar 05Sale58.532,240131,10718,803Mar 05 05:34 PM
Snodgres JonChief Financial OfficerFeb 28Sale58.881,875110,40024,946Mar 04 06:58 PM
KURIYEL RALFSenior VP, R&DFeb 28Sale59.1618510,94516,343Mar 04 06:52 PM
Hunt AnthonyChief Executive OfficerFeb 28Sale59.017,475441,100242,657Mar 04 06:52 PM
KURIYEL RALFSenior VP, R&DDec 18Sale54.4431116,93112,294Dec 20 04:22 PM
Snodgres JonCFONov 26Option Exercise27.1231,753861,13252,652Nov 28 04:43 PM
Snodgres JonCFONov 26Sale63.4931,7532,015,91520,899Nov 28 04:43 PM
RYAN THOMAS F JRDirectorNov 05Sale65.751,763115,9203,225Nov 06 06:29 PM